Clopidogrel and proton pump inhibitor use a review of the evidence on safety
The objective of this report is to assess the current evidence on the impact of PPIs on adverse events in adults being treated with clopidogrel dual antiplatelet therapy (DAPT) or monotherapy following percutaneous coronary intervention (PCI) involving stents
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 14 March 2017
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to assess the current evidence on the impact of PPIs on adverse events in adults being treated with clopidogrel dual antiplatelet therapy (DAPT) or monotherapy following percutaneous coronary intervention (PCI) involving stents |
|---|---|
| Physical Description: | 1 PDF file (49 pages) illustrations |